Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.54 |
| ▸ | SPHK1 | Q9NYA1 | 7/20 | 0.43 |
| ▸ | SPHK2 | Q9NRA0 | 6/20 | 0.43 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.41 |
| ▸ | PRKCG | P05129 | 2/20 | 0.41 |
| ▸ | PRKCB | P05771 | 2/20 | 0.41 |
| ▸ | PRKCA | P17252 | 2/20 | 0.41 |
| ▸ | PRKCH | P24723 | 2/20 | 0.41 |
| ▸ | PRKCI | P41743 | 2/20 | 0.41 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.41 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.41 |
| ▸ | PRKCZ | Q05513 | 2/20 | 0.41 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.41 |
| ▸ | PRKD1 | Q15139 | 2/20 | 0.41 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.40 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1668995 | 1.00 | ALDH1A1 (0.58) | ALDH1A1EPHX1SPHK1SPHK2PRKD3 | |
| SCHEMBL3093222 | 1.00 | ALDH1A1 (0.58) | ALDH1A1EPHX1SPHK1SPHK2PRKD3 | |
| SCHEMBL14779270 | 1.00 | ALDH1A1 (0.58) | ALDH1A1EPHX1SPHK1SPHK2PRKD3 | |
| SCHEMBL14779341 | 1.00 | ALDH1A1 (0.58) | ALDH1A1EPHX1SPHK1SPHK2PRKD3 | |
| SCHEMBL14779416 | 1.00 | ALDH1A1 (0.58) | ALDH1A1EPHX1SPHK1SPHK2PRKD3 | |
| SCHEMBL6896512 | 1.00 | ALDH1A1 (0.58) | ALDH1A1EPHX1SPHK1SPHK2PRKD3 | |
| SCHEMBL2754170 | 0.98 | ALDH1A1 (0.54) | ALDH1A1EPHX1SPHK1SPHK2PRKD3 | |
| SCHEMBL5945225 | 0.95 | ALDH1A1 (0.58) | ALDH1A1EPHX1SPHK1SPHK2PRKD3 | |
| SCHEMBL5945122 | 0.95 | ALDH1A1 (0.58) | ALDH1A1EPHX1SPHK1SPHK2PRKD3 | |
| SCHEMBL5945096 | 0.95 | ALDH1A1 (0.58) | ALDH1A1EPHX1SPHK1SPHK2PRKD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12551433-B1 | Associated forms of nonsteroidal anti-inflammatory drugs and local anesthetics | INNOVATOR THERAPEUTICS, LLC (US) | 2026-02-17 | — | — | US | disclosed |
| WO-2023201859-A1 | EPRISTERIDE EXTERNAL PREPARATION FOR PREVENTING AND TREATING ANDROGENETIC ALOPECIA | 江苏联环药业股份有限公司 | 2023-10-26 | — | — | WO | disclosed |
| CN-114931546-A | Epipret external preparation for preventing and treating androgenetic alopecia | 江苏联环药业股份有限公司 | 2022-08-23 | — | — | CN | disclosed |
| US-20210330667-A1 | TOPICAL COMPOSITION OF NALBUPHINE AND METHOD FOR TREATING PRURITUS CONDITION, PAIN, OR INFLAMMATORY CONDITION BY USING THE SAME | LUMOSA THERAPEUTICS CO., LTD. (TW) | 2021-10-28 | — | — | US | disclosed |
| EP-2303265-B1 | STABLE TOPICAL FORMULATION COMPRISING VORICONAZOLE | GLENMARK PHARMACEUTICALS LTD (IN) | 2014-12-10 | — | — | EP | disclosed |
| US-20110105448-A1 | Stable Topical Formulation Comprising Voriconazole | GLENMARK PHARMACEUTICALS LIMITED (IN) | 2011-05-05 | — | — | US | disclosed |
| EP-2303265-A2 | STABLE TOPICAL FORMULATION COMPRISING VORICONAZOLE | Glenmark Pharmaceuticals Limited (IN) | 2011-04-06 | — | — | EP | disclosed |
| WO-2010084505-A2 | STABLE TOPICAL FORMULATION COMPRISING VORICONAZOLE | GLENMARK PHARMACEUTICALS LIMITED (IN) | 2010-07-29 | — | — | WO | disclosed |
| CN-101203198-A | Enhancement of macrolide penetration through human skin | MACROCHEM CORP (US) | 2008-06-18 | — | — | CN | disclosed |
| EP-1879593-A2 | LOW DOSE ADMINISTRATION OF A TOPICAL COMPOSITION | MacroChem Corporation (US) | 2008-01-23 | — | — | EP | disclosed |
| WO-2005000241-A2 | COMPOSITONS AND METHODS FOR TOPICAL ADMINISTRATION | MACROCHEM CORPORATION (US) | 2005-01-06 | — | — | WO | disclosed |
| EP-0983037-B1 | ANTIFUNGAL NAIL LACQUER | MACROCHEM CORP (US) | 2003-05-02 | — | — | EP | disclosed |
| US-20030082226-A1 | Non-steroidal antiinflammatory drug formulations for topical application to the skin | SAMOUR CARLOS M (US) | 2003-05-01 | — | — | US | disclosed |
| US-6224887-B1 | MIXTURE CONTAINING PENETRATION PROMOTER, WATER INSOLUBLE FILM FORMING POLYMER AND SOLVENT | MACROCHEM CORPORATION | 2001-05-01 | — | — | US | disclosed |
| US-5976566-A | INCLUDING IN THE FORMULATION 2-HYDROCARBYL-1,3-DIOXOLANE, 1,3-DIOXANE OR AN ACETAL, AS SKIN PENETRATION ENHANCING COMPOUND. | MACROCHEM CORPORATION (US) | 1999-11-02 | — | — | US | disclosed |
| US-5968919-A | CONTAINING PENETRATION ENHANCER OF (HYDROCARBYL-SUBSTITUTED) 1,3-DIOXOLANE, 1,3-DIOXANE OR ACETAL | MACROCHEM CORPORATION (US) | 1999-10-19 | — | — | US | disclosed |
| US-5620980-A | TOPICALLY APPLYING MINOXIDIL AND PENETRATION ENHANCING AMOUNT OF 2-ALKYL-1,3-DIOXOLANE TO SKIN | MACROCHEM CORPORATION (US) | 1997-04-15 | — | — | US | disclosed |
| EP-0268460-B1 | NEW PERCUTANEOUS ABSORPTION ENHANCERS, COMPOSITIONS CONTAINING SAME AND METHOD OF USE | Macrochem Corporation (US) | 1991-11-06 | — | — | EP | disclosed |
| US-4861764-A | Percutaneous absorption enhancers, compositions containing same and method of use | MACRO CHEM. CORP. (US) | 1989-08-29 | — | — | US | disclosed |
| EP-0268460-A1 | New percutaneous absorption enhancers, compositions containing same and method of use | Macrochem Corporation (US) | 1988-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030082226-A1 | Non-steroidal antiinflammatory drug formulations for topical application to the skin | PTGES3, PTGS1, PTGES | ALDH1A1 354/4885EPHX1 537/4885SPHK1 209/4885 |
| US-12551433-B1 | Associated forms of nonsteroidal anti-inflammatory drugs and local anesthetics | TRPV1, TRPA1, TRPC5 | ALDH1A1 1191/4885EPHX1 2021/4885SPHK1 2124/4885 |
| US-20110105448-A1 | Stable Topical Formulation Comprising Voriconazole | ERG28, CYP51A1, PIK3C3 | ALDH1A1 4022/4885EPHX1 3530/4885SPHK1 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.